Gabapentin
Product Images NDC 0440-7559

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0440-7559). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Liberty Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

930a0c1e-figure-01 (Gabapentin 300 mg 270 Caps For Amneal 1)

Chemical structure of gabapentin showing a cyclohexane ring attached to an aminomethyl group and a carboxymethyl group.*

FDA Label Image

930a0c1e-figure-02 (Gabapentin 300 mg 270 Caps For Amneal 2)

A line graph depicting mean pain scores over an 8-week period comparing placebo to Gabapentin at 3600 mg/day. The X-axis shows weeks from baseline to week 8, and the Y-axis shows mean pain score from 0 to 10. Two study periods are indicated: a 4-week dose titration period and a 4-week fixed dose period. Gabapentin shows a significant decrease in mean pain scores compared to placebo, with statistical significance marked by double asterisks.*

FDA Label Image

930a0c1e-figure-03 (Gabapentin 300 mg 270 Caps For Amneal 3)

A line graph titled with a dose titration and fixed dose period timeline. The graph shows mean pain scores over 7 weeks, comparing placebo and two doses of Gabapentin (1800 mg/day and 2400 mg/day). Both Gabapentin doses demonstrate reduced mean pain scores compared to placebo during the study period.*

FDA Label Image

930a0c1e-figure-04 (Gabapentin 300 mg 270 Caps For Amneal 4)

A bar graph showing the percentage of responders at the endpoint for two studies involving Gabapentin (GBP) and placebo (PBO). Study 1 compares PBO with GBP at 3600 mg, and Study 2 compares PBO with GBP at 1800 mg and 2400 mg. The graph includes statistical significance markers (p < 0.01 and p < 0.001) for Gabapentin groups showing higher response rates than placebo.*

FDA Label Image

930a0c1e-figure-05 (Gabapentin 300 mg 270 Caps For Amneal 5)

A scatter plot chart showing the percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis. The chart compares three studies labeled a, b, and c, with data points for doses of approximately 600 mg, 900 mg, 1200 mg, and 1800 mg, illustrating varying percentage differences associated with each study and dose level.*

FDA Label Image

Image Label (Gabapentin 300 mg 270 Caps For Amneal 6)

The packaging label for Gabapentin 300 mg capsules, containing 270 capsules, from Liberty Pharmaceuticals, Inc. It is marked as RX Only and includes the generic name Gabapentin with the brand name Neurontin noted. The label shows an NDC number 00440-7559-94, manufacturing by Amneal Pharmaceuticals of NY, and packaging by Aidarex Pharmaceuticals LLC in Corona, CA. It includes instructions for doctor and patient information, capsule description, lot, and expiration date fields, and a caution about storage and keeping out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.